Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2022 01:00 ET | Source: Molecular Partners

Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
January 18, 2022 01:00 ET | Source: Molecular Partners

Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19

Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the programFinancial terms include milestone payment of CHF150 million to Molecular...
January 13, 2022 17:00 ET | Source: Molecular Partners

Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations

ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
January 10, 2022 01:17 ET | Source: Molecular Partners

Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19

Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic...
January 05, 2022 16:05 ET | Source: Molecular Partners

Molecular Partners to Present at Upcoming Healthcare Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
December 15, 2021 01:00 ET | Source: Molecular Partners

Molecular Partners to Host Oncology Day (Virtual)

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
December 14, 2021 01:00 ET | Source: Molecular Partners

Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology

Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis’ in radioligand therapy to explore the potential for novel targeted therapies for cancerNovartis...
December 12, 2021 16:00 ET | Source: Molecular Partners

Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies

Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency...
December 09, 2021 01:00 ET | Source: Molecular Partners

Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December

Program overview and study design for MP0317 to be presented at ESMO Immuno-OncologyPreclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASHOncology R&D Day to...
December 06, 2021 01:00 ET | Source: Molecular Partners

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021

First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...